HBIO
Price
$2.02
Change
+$0.04 (+2.02%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
184.01M
50 days until earnings call
QTRX
Price
$8.57
Change
-$0.54 (-5.93%)
Updated
Jan 14 closing price
Capitalization
907.82M
48 days until earnings call
Ad is loading...

HBIO vs QTRX

Header iconHBIO vs QTRX Comparison
Open Charts HBIO vs QTRXBanner chart's image
Harvard Bioscience
Price$2.02
Change+$0.04 (+2.02%)
Volume$1.36K
Capitalization184.01M
Quanterix
Price$8.57
Change-$0.54 (-5.93%)
Volume$1.76M
Capitalization907.82M
HBIO vs QTRX Comparison Chart
Loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HBIO vs. QTRX commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a StrongBuy and QTRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (HBIO: $2.02 vs. QTRX: $8.57)
Brand notoriety: HBIO and QTRX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HBIO: 88% vs. QTRX: 340%
Market capitalization -- HBIO: $184.01M vs. QTRX: $907.82M
HBIO [@Medical Specialties] is valued at $184.01M. QTRX’s [@Medical Specialties] market capitalization is $907.82M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileQTRX’s FA Score has 1 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • QTRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both HBIO and QTRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 4 TA indicator(s) are bullish while QTRX’s TA Score has 3 bullish TA indicator(s).

  • HBIO’s TA Score: 4 bullish, 3 bearish.
  • QTRX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, HBIO is a better buy in the short-term than QTRX.

Price Growth

HBIO (@Medical Specialties) experienced а -6.05% price change this week, while QTRX (@Medical Specialties) price change was -27.31% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.23%. For the same industry, the average monthly price growth was -0.02%, and the average quarterly price growth was -1.16%.

Reported Earning Dates

HBIO is expected to report earnings on May 01, 2025.

QTRX is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Medical Specialties (-3.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QTRX($908M) has a higher market cap than HBIO($184M). HBIO YTD gains are higher at: -4.265 vs. QTRX (-19.379). HBIO has higher annual earnings (EBITDA): 8.03M vs. QTRX (-39.79M). QTRX has more cash in the bank: 321M vs. HBIO (4.28M). QTRX (41.5M) and HBIO (42.8M) have identical debt. QTRX has higher revenues than HBIO: QTRX (121M) vs HBIO (112M).
HBIOQTRXHBIO / QTRX
Capitalization184M908M20%
EBITDA8.03M-39.79M-20%
Gain YTD-4.265-19.37922%
P/E RatioN/AN/A-
Revenue112M121M93%
Total Cash4.28M321M1%
Total Debt42.8M41.5M103%
FUNDAMENTALS RATINGS
HBIO vs QTRX: Fundamental Ratings
HBIO
QTRX
OUTLOOK RATING
1..100
2252
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9593
PRICE GROWTH RATING
1..100
9092
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a48

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QTRX's Valuation (32) in the Pharmaceuticals Major industry is significantly better than the same rating for HBIO (99) in the Biotechnology industry. This means that QTRX’s stock grew significantly faster than HBIO’s over the last 12 months.

QTRX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as HBIO (100) in the Biotechnology industry. This means that QTRX’s stock grew similarly to HBIO’s over the last 12 months.

QTRX's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as HBIO (95) in the Biotechnology industry. This means that QTRX’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's Price Growth Rating (90) in the Biotechnology industry is in the same range as QTRX (92) in the Pharmaceuticals Major industry. This means that HBIO’s stock grew similarly to QTRX’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for QTRX (100) in the Pharmaceuticals Major industry. This means that HBIO’s stock grew significantly faster than QTRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIOQTRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
Momentum
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
88%
MACD
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
74%
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
Bearish Trend 22 days ago
82%
Bearish Trend 7 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HEONX15.700.22
+1.42%
Hartford Climate Opportunities C
ADLVX27.060.27
+1.01%
Adler Value Institutional
MEFAX12.960.07
+0.54%
MassMutual Mid Cap Growth A
FOPIX18.930.03
+0.16%
Fidelity Advisor Intl Sm Cap Opps I
HFETX44.11N/A
N/A
Janus Henderson European Focus T

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with CTKB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then CTKB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
+2.02%
CTKB - HBIO
46%
Loosely correlated
+0.69%
SGHT - HBIO
46%
Loosely correlated
-2.78%
XRAY - HBIO
45%
Loosely correlated
-3.22%
CRL - HBIO
44%
Loosely correlated
-6.34%
ICUI - HBIO
44%
Loosely correlated
+1.85%
More